Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand
| Autor: | Pattara Leelahavarong, Usa Chaikledkaew, Thanaporn Bussabawalai, Yot Teerawattananon, Watsamon Thongsri, Kritvikrom Durongpisitkul, Suthep Wanitkun |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Budgets Heart Defects Congenital Drug medicine.medical_specialty Pathology Heart disease Sildenafil Cost-Benefit Analysis Hypertension Pulmonary Vasodilator Agents media_common.quotation_subject 030204 cardiovascular system & hematology Drug Costs Sildenafil Citrate 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine health care economics and organizations media_common Cost–utility analysis business.industry Health Policy Standard treatment General Medicine Budget impact Thailand medicine.disease Epoprostenol Markov Chains Beraprost chemistry Cost utility Quality-Adjusted Life Years Drugs Essential business medicine.drug |
| Zdroj: | Expert Review of Pharmacoeconomics & Outcomes Research. 16:525-536 |
| ISSN: | 1744-8379 1473-7167 |
| DOI: | 10.1586/14737167.2016.1120672 |
| Popis: | This study aims to compare the lifetime costs and health outcomes of both first-line and sequential combination treatments with standard treatment for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) (PAH-CHD) patients.A cost-utility analysis was performed using a Markov model based on a societal perspective. One-way and probabilistic sensitivity analyses were performed to investigate the effect of parameter uncertainty.As first-line treatments, both beraprost (incremental cost-effectiveness ratio (ICER) = 192,752 and 201,308 Thai baht (THB) per quality-adjusted life year (QALY) gained) and sildenafil (ICER = 249,770 and 226,802 THB per QALY gained) seemed cost-effective for PAH-CHD patients aged ≤30 years in functional classes II and III, respectively, while no treatment was cost-effective for the sequential combination therapy.Sildenafil should be included in the National Drug List of Essential Medicines as the first-line treatment for PAH-CHD, and its price per dose should be negotiated to be reduced by 43-57%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|